SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Billie Holiday

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-04-27
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week buprenorphine check, seen the same day by addiction medicine. [S]

History of Present Illness

Ms. Holiday returns one week after starting buprenorphine with naloxone and is seen by Dr. Ortiz of addiction medicine on the same day. She took half a film on the first day and one film daily since, under the tongue each morning, without missing a dose. She has used no heroin or other opioids. She had no withdrawal, but cravings come back each evening, most of all after a show. She has had mild constipation and no drowsiness. She picked up two naloxone two-packs; her friend came with her and was shown how to use them. She is still drinking four or five drinks on performance nights. She read her results from last week by phone. She says she came back because nobody lectured her at the first visit. [S]

ElementDetail
Buprenorphine8 mg daily for six days, every dose taken
Opioid useNone
CravingsEvery evening, strongest after shows
Side effectsMild constipation
NaloxoneTwo two-packs dispensed; her friend trained
AlcoholFour or five drinks on performance nights

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo sweats, chills, or drowsiness
GastrointestinalPositiveMild constipation; no nausea, vomiting, or abdominal pain
PsychiatricPositiveEvening cravings; mood low at times; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-27Body height165cmS
2026-04-27Body weight68.2kgS
2026-04-27Body mass index (BMI) [Ratio]25.1kg/m2S
2026-04-27Systolic blood pressure122mm[Hg]S
2026-04-27Diastolic blood pressure78mm[Hg]S
2026-04-27Heart rate78/minS
2026-04-27Respiratory rate14/minS
2026-04-27Body temperature36.7CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Physical Exam

Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and engaged; blood pressure 122/78, pulse 78
EyesPupils normal in size; no yawning, tearing, or gooseflesh
PsychiatricCalm; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, adherence, cravings, withdrawal, and side effectsEvery visitCompleted today8 mg daily, every dose taken; evening cravings; no withdrawal or sedation; increased to 16 mg
Self-managementVisit frequencyEvery 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stableCompleted todaySeen one week after starting
LaboratoryUrine drug testing, including fentanyl, explained as part of care rather than as a test of trustAt the start, then about monthly early in treatment and as neededCompleted todayBuprenorphine and norbuprenorphine present; no fentanyl or other opioids
Medication safetyPrescription drug monitoring program checkBefore each buprenorphine prescriptionCompleted todayNo other controlled-substance prescriptions
Medication safetyNaloxone at home and in her bag, and a trained companionAt the start; check and replace at each visitCompleted todayTwo two-packs dispensed; her friend trained
Self-managementOverdose prevention: never using alone and fentanyl test stripsEvery visitCompleted todayReviewed; fentanyl test strips given
Self-managementCounseling and peer recovery supportOffered to everyone; not a condition of medicationCompleted todayShe chose weekly counseling and a peer recovery coach
Self-managementOral care on sublingual buprenorphineAt the start and yearlyCompleted todayAfter the film dissolves, swish water and swallow, and wait an hour before brushing; dental visit advised
SurveyDrinking and PEthPEth at intake and at each check while drinking continues; AUDIT-C yearlyUp to datePEth 312 ng/mL and AUDIT-C 8 a week ago; four or five drinks on performance nights
Medication safetyAcamprosate adherence and kidney functionKidney function before starting; adherence every visitCompleted todayCreatinine 0.72 mg/dL and eGFR 113 a week ago; acamprosate started
Medication safetyNaltrexone for alcohol use disorderFirst-line for alcohol use disorder unless opioids are neededNot indicatedContraindicated with buprenorphine
ExaminationAlcohol withdrawal riskEvery visitCompleted todayNo history of withdrawal seizures or delirium; no withdrawal symptoms
Medication safetyThiamineWhile drinking heavilyCompleted todayTaking thiamine 100 mg daily
LaboratoryLiver tests (AST, ALT, GGT, albumin, bilirubin)At intake, then every 1 to 3 months while drinking is heavy, and yearlyUp to dateAST 52, ALT 38, GGT 84 U/L a week ago; albumin and bilirubin normal
LaboratoryFIB-4 fibrosis scoreAt intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 yearsUp to date1.18 a week ago (age 33, AST 52, ALT 38, platelets 236): low risk
ImagingVibration-controlled transient elastographyIf FIB-4 is 1.3 or higherNot indicatedFIB-4 below 1.3
LaboratoryHepatitis C, hepatitis B, and HIV testingAt entry to care, then yearly while any drug use continuesUp to dateAll nonreactive a week ago
Self-managementHepatitis A and B vaccinesHepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apartUp to dateFirst doses a week ago; hepatitis B dose 2 next visit
SurveyDepression screen (PHQ-9)At intake and at each recovery visit while symptoms are presentUp to datePHQ-9 9 a week ago; next at the five-week visit
SurveySuicide and overdose risk review, safety plan, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; overdose risk lowered by buprenorphine and naloxone; the 988 Suicide & Crisis Lifeline saved in her phone
LaboratoryPregnancy test and contraceptionBefore starting buprenorphine; contraception discussedUp to dateUrine pregnancy test negative a week ago
ReferralAddiction medicine consultationAt the start of treatmentCompleted todaySeen by Dr. Ortiz today

Goal progress:

Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Visit in two weeks; she leaves on tour in five days and will call in, with the in-person visit when she returns. Counselor weekly. Results by phone. Next scheduled visit 2026-05-26: five-week recovery review and second hepatitis B vaccine. [S]